Detailansicht

Wissensnetz

Person

Martin Griesshammer

Arzt

Name	Martin Griesshammer
Ort	Deutschland
Geschlecht	männlich
Beruf	Arzt (charakteristischer Beruf)
Variante	Fritz-Albert M. Griesshammer Fritz Albert Martin Griesshammer
Weitere Angaben	Chefarzt Abteilung Hämatologie/Onkologie und Palliativmedizin, Johannes Wesling Klinikum Minden
Quelle	Internet
Datensatztyp	Person
GND-Nummer	142796360
Datensatz-ID	142796360
Beteiligt an alle anzeigen FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN) FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN) Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN) Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN) Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera : futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group P1055: Clinical and genetic results of the phase IB/II TRIAL MPNSG-0212: ruxolitinib plus pomalidomide in myelofibrosis with anemia Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH) Diagnostik und Therapie der Polycythaemia vera im Jahre 2015 Diagnostik und Therapie der Polycythaemia vera im Jahre 2015 Aktuelle Therapieoptionen bei der Myelofibrose FLT3 mutations in Early T-Cell Precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors Wertigkeit gerinnungsphysiologischer Untersuchungen zur Beurteilung der hämorrhagischen und thrombophilen Diathese bei Patienten mit essentieller Thrombozythämie Der Einfluss der makrophagentoxischen Substanz Carrageenan auf die allogene Lebertransplantation beim Schwein

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Martin Griesshammer

FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)

FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)

Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)

Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera : futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

P1055: Clinical and genetic results of the phase IB/II TRIAL MPNSG-0212: ruxolitinib plus pomalidomide in myelofibrosis with anemia

Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry

Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study

Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)

Diagnostik und Therapie der Polycythaemia vera im Jahre 2015

Diagnostik und Therapie der Polycythaemia vera im Jahre 2015

Aktuelle Therapieoptionen bei der Myelofibrose

FLT3 mutations in Early T-Cell Precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors

Wertigkeit gerinnungsphysiologischer Untersuchungen zur Beurteilung der hämorrhagischen und thrombophilen Diathese bei Patienten mit essentieller Thrombozythämie

Der Einfluss der makrophagentoxischen Substanz Carrageenan auf die allogene Lebertransplantation beim Schwein